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et al12 published the first large and comprehensive 
study analyzing the genetic background of natu‑
ral anticoagulant deficiencies in the Polish Slavic 
population. The authors evaluated the causal ge‑
netic background of 90 unrelated patients (mean 
[SD] age, 40.1 [13.2] years) with AT (n = 35), PC 
(n = 28), or PS (n = 27) deficiencies, screening for 
mutations using the Sanger sequencing and mul‑
tiplex ligation ‑dependent probe amplification. 
Twenty novel mutations were described, all pres‑
ent in a heterozygous form. The frequency of mis‑
sense, nonsense, and splice ‑site mutations was 
similar for all 3 genes/proteins.
Currently, more than 250 loss ‑of ‑function 
mutations have been identified in the AT gene 
(SERPIN1), located at chromosome 1q 23–25.6 
Among the deficiencies of natural anticoagu‑
lants, AT deficiency has the lowest prevalence 
(0.02%–0.2% in the general population).1,13 This 
deficiency is considered the most severe among 
the inherited thrombophilias. AT deficiency is 
transmitted with an autosomal dominant trait 
and its penetrance is very high. A wide variety 
of mutations can lead to type I defects, charac‑
terized by decreased activity and antigen levels. 
Type II defects, caused by missense mutations, are 
functional defects associated with normal AT an‑
tigen levels but with impaired inhibitory activi‑
ty due to the production of a variant protein.1,6,13 
The dysfunction may affect the reactive site (IIRS) 
or the heparin ‑binding site (IIHBS) or both (pleio‑
tropic effect, IIPE). The reactive site, which is lo‑
cated at the carboxy ‑terminal part of the protein, 
is encoded by exon 7 of the SERPINC1 gene, while 
the heparin ‑binding site is encoded by exons 2 
and 3.1,7 In the study by Wypasek et al,12 the caus‑
ative mutation was found in 26 of 35 patients 
with AT deficiency, leading to a mutation detec‑
tion rate of 74%. In individuals with AT activity 
below 70%, the mutation detection rate was 90%. 
In 50% of the patients, mutations were located 
Understanding the causes of excessive blood clot‑
ting has been a long ‑time challenge. As early as 
in 1856, Rudolf Virchow postulated in his well 
known theory of the triad that one of the key 
components in the etiology of thrombosis is 
the “change in the composition of blood”.1 Nev‑
ertheless, more than 100 years had to pass after 
this groundbreaking observation for the first case 
of inherited antithrombin (AT) deficiency to be 
published by Egeberg in 1965.2 The first function‑
al AT defect, named AT Budapest was published 
by Sas et al3 in 1974, followed by a series of re‑
ports on protein C (PC) and protein S (PS) defi‑
ciency in the 1980s.1,4,5 Today, the term “throm‑
bophilia” is used to describe a tendency to devel‑
op venous thromboembolism due to abnormal‑
ities of blood coagulation that can be inherited, 
acquired, or both.6 Inherited thrombophilias in‑
clude loss ‑of ‑function mutations of the genes en‑
coding the natural anticoagulant proteins leading 
to AT, PC, and PS deficiencies, as well as the gain‑
‑of ‑function mutations comprising of the relative‑
ly frequent factor V Leiden mutation and a muta‑
tion in the prothrombin gene (FII20210A). In ad‑
dition, data are accumulating on further heredi‑
tary factors, including the non ‑O blood types.1,6,7
Our knowledge on inherited deficiencies 
of natural anticoagulants has evolved greatly 
since the first publication by Egeberg.2 Howev‑
er, due to the very low prevalence of these dis‑
orders in the general population, the majority 
of this knowledge is still based on case reports 
and expert opinions.7,8 High ‑quality research on 
the genotype–phenotype associations and struc‑
tural–functional studies are of great importance 
when attempting to unravel the pathophysiology 
of these rare diseases. Surprisingly, until now only 
a few case reports have been published on Polish 
AT/PC/PS ‑deficient patients with known causal 
mutations.9-11 In this issue of the Polish Archives of 
Internal Medicine (Pol Arch Intern Med), Wypasek 
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measured by either clotting ‑based assays or chro‑
mogenic types of assays: in both cases, a number 
of interfering factors are known, leading to a po‑
tential overestimation or underestimation of PC 
activity.14 Measurement of PS levels is further 
complicated by the fact that PS is partitioned in 
plasma between free functional PS and the por‑
tion bound to the complement protein, C4b‑
‑binding protein. When testing for PS deficien‑
cy, free PS antigen level is considered the “func‑
tional” anticoagulant fraction of PS (although it 
is not a true measure of activity) and the clotting‑
‑based PS activity assay is not recommended for 
the initial screening of PS levels.14 Importantly, 
in patients with the factor V Leiden mutation, 
PC and PS activities as measured by commercial 
clotting assays might be falsely decreased, lead‑
ing to a potential misdiagnosis of type II PC or 
PS deficiency.7
Given the complexity of the diagnosis, the use‑
fulness of molecular genetic analysis has been em‑
phasized not only for AT deficiency but also for 
PC and PS deficiencies. Unfortunately, as com‑
pared with AT deficiency, the mutation detec‑
tion rate by Sanger sequencing is often low for 
PC and PS deficiencies, suggesting that testing 
of patients with PC levels above 70% and free PS 
levels above 55% might not be expedient.7 This 
is in line with the findings by Wypasek et al,12 
reporting that for PC levels below 70%, the mu‑
tation detection rate was above 90%, while for 
free PS levels below 40%, the mutation detec‑
tion rate was 77%. It is also important to men‑
tion that the molecular diagnostics of PS defi‑
ciency is often complicated by the presence of 
PROS2, a pseudogene.1,7 In the study by Wypas‑
ek et al,12 8 PROC mutations and 3 PROS1 muta‑
tions were reported for the first time. The ma‑
jority of the newly detected PROC gene muta‑
tions (Cys387Tyr, p.Val434Ala, and p.Leu320Pro) 
clustered in exon 9, within the region encoding 
the catalytic domain. These variants may poten‑
tially affect substrate binding, leading to type 
II disorders. The newly found p.Cys64Tyr muta‑
tion, located in the gamma ‑carboxyglutamic do‑
main of the PC structure and the p.Cys175Arg 
mutation, located in the EGF ‑2 domain most 
probably lead to type I PC deficiency. Another 
novel mutation, p.Gln226*, may yield a truncat‑
ed protein product. Among the new mutations 
described in the PROS1 gene, the p.Cys126Gly 
and the p.Cys241* are located in the EGF ‑like 1 
and the EGF ‑like 3 calcium ‑binding domains, re‑
spectively, most probably leading to type I defi‑
ciencies. Instead, in case of the newly discovered 
p.Gly489Arg mutation, located in the laminin‑
‑G‑like 2 domain, the C4BP‑binding sites are like‑
ly to be comprised, leading to type III disorder.
Today, consensus is still lacking as to who, 
when, and how should be tested for thrombo‑
philia.8,15 More research is needed in order to fa‑
cilitate method development and to clarify many 
unresolved topics regarding the rare inherited 
forms. If genetic analysis helps answer any of 
at exon 2 or exon 7. These results confirm previ‑
ous findings in other populations that molecu‑
lar genetic testing is a useful diagnostic tool for 
confirming inherited AT deficiencies, although 
in other populations molecular testing was sug‑
gested in the AT activity range of 70% to 80% as 
well.7 Moreover, a genetic analysis can be partic‑
ularly helpful when it comes to the differentia‑
tion between AT deficiency subtypes, thus facil‑
itating patient care. Among the newly detected 
SERPINC1 gene mutations described by Wypas‑
ek et al,12 type I deficiency is likely in the case of 
p.Glu338*, p.Val458_Cys462del insGly, c.948delC, 
p.Thr433Ser and c.625 ‑2A>G mutations. The new 
p.Ala118Pro and the p.Gly125Cys variants are lo‑
cated in highly conserved serpin residues and thus 
are likely to result in the disturbance of the cor‑
rect folding of AT.
PC and PS deficiencies are transmitted as au‑
tosomal dominant traits with incomplete pene‑
trance.1,7 More than 250 loss ‑of ‑function muta‑
tions have been reported in the PC gene (PROC), 
located at chromosome 2q13 ‑q14.6 Over 150 mu‑
tations have been identified so far in the PROS1 
gene, responsible for inherited PS deficiency.7 
The majority of these reported mutations are mis‑
sense mutations, short deletions or insertions, 
but large deletions have been identified to be rel‑
atively common as well. Both deficiencies have 
similar clinical presentation: heterozygotes ex‑
perience early and recurrent episodes of venous 
thromboembolism, while the extremely rare cas‑
es of homozygotes exhibit the severe clinical pic‑
ture of neonatal purpura fulminans.1,6,7 PC defi‑
ciency is classified on the basis of the plasma lev‑
els of the enzymatic activity and antigen, and, 
similarly to AT deficiency, it can be divided into 
2 subtypes: in the case of type I deficiency, there 
is a parallel reduction in the PC activity and an‑
tigen levels, while in the case of the much rarer 
type II deficiency, normal antigen levels are ac‑
companied by reduced functional activity.14 As for 
PS deficiency, 3 types have been described: type I 
is a quantitative deficiency with decreased plas‑
ma levels of functional and immunoreactive to‑
tal and free PS, type II is a qualitative deficiency 
with decreased cofactor activity but normal to‑
tal and free PS levels, while type III is a quanti‑
tative disorder with reduced functional activity 
and free PS levels but normal total PS levels.1,6,14 
It has been proposed by several studies that type 
I and III deficiencies are in fact phenotypic vari‑
ants of the same genetic disease.7
Due to a number of methodological issues, 
the diagnosis of AT/PC/PS deficiencies can be 
a challenging task. Functional assays of all 3 pro‑
teins have several advantages and disadvantag‑
es.7,13,14 For the correct measurement of AT activ‑
ity, bovine thrombin‑ and FXa inhibition ‑based 
tests are both advisable, as no single product ap‑
pears to recognize all functional defects.12,13 More‑
over, for the detection of type IIHBS defects, pro‑
gressive AT assays, performed in the absence 
of heparin, are also useful.13 PC activity can be 
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the questions raised, its execution is definitely 
timely and worthwhile.
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